F Marmé1, W Werft2, A Benner2, B Burwinkel3, P Sinn4, C Sohn5, P Lichter6, M Hahn6, A Schneeweiss5. 1. Department of Obstetrics and Gynecology, University Hospital Heidelberg; Department of Molecular Genetics. Electronic address: Frederik.Marme@med.uni-heidelberg.de. 2. Department of Biostatistics. 3. Department of Obstetrics and Gynecology, University Hospital Heidelberg; Department of Molecular Epidemiology, German Cancer Research Center. 4. Institute of Pathology, University of Heidelberg, Heidelberg, Germany. 5. Department of Obstetrics and Gynecology, University Hospital Heidelberg. 6. Department of Molecular Genetics.
Abstract
BACKGROUND: A single-nucleotide polymorphism (SNP) in the FGFR4 gene is associated with poor prognosis in solid tumors. A recent study presented the first evidence that FGFR4 Arg388 could predict resistance to adjuvant chemotherapy in breast cancer. The present study evaluates the potential of this SNP to predict response to neoadjuvant chemotherapy (NCT) for primary breast cancer (PBC). METHODS: As part of a randomized phase II trial, 257 patients received eitherdoxorubicin-cyclophosphamide (AC) or doxorubicin-pemetrexed (AP) followed by docetaxel (Doc; Taxotere) as NCT for T2-4/N0-2/M0 PBC. FGFR4 genotype analyzed on germline DNA was correlated with clinicopathologic variables, clinical response, and pathological complete response (pCR) using univariate and multivariate analyses. RESULTS: Only axillary lymph node status was associated with FGFR4 Arg388 [odds ratio (OR) 1.82, P = 0.03]. Joint analysis of both treatment arms revealed a correlation of FGFR4 Arg388 with clinical response (OR 2.14, P = 0.03) but not with pCR. In the AC-Doc arm, however, FGFR4 Arg388 was a strong predictor of pCR in the multivariate analysis (OR 3.79, P = 0.03). A significant interaction between FGFR4 genotype and treatment (P = 0.01) was found, indicating a therapy-specific effect. CONCLUSION: We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC.
RCT Entities:
BACKGROUND: A single-nucleotide polymorphism (SNP) in the FGFR4 gene is associated with poor prognosis in solid tumors. A recent study presented the first evidence that FGFR4Arg388 could predict resistance to adjuvant chemotherapy in breast cancer. The present study evaluates the potential of this SNP to predict response to neoadjuvant chemotherapy (NCT) for primary breast cancer (PBC). METHODS: As part of a randomized phase II trial, 257 patients received either doxorubicin-cyclophosphamide (AC) or doxorubicin-pemetrexed (AP) followed by docetaxel (Doc; Taxotere) as NCT for T2-4/N0-2/M0 PBC. FGFR4 genotype analyzed on germline DNA was correlated with clinicopathologic variables, clinical response, and pathological complete response (pCR) using univariate and multivariate analyses. RESULTS: Only axillary lymph node status was associated with FGFR4Arg388 [odds ratio (OR) 1.82, P = 0.03]. Joint analysis of both treatment arms revealed a correlation of FGFR4Arg388 with clinical response (OR 2.14, P = 0.03) but not with pCR. In the AC-Doc arm, however, FGFR4Arg388 was a strong predictor of pCR in the multivariate analysis (OR 3.79, P = 0.03). A significant interaction between FGFR4 genotype and treatment (P = 0.01) was found, indicating a therapy-specific effect. CONCLUSION: We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC.
Authors: Ashraf Dallol; Abdelbaset Buhmeida; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Aisha Elaimi; Mourad Assidi; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Shadi S Alkhayyat; Mohammed H Al-Qahtani Journal: Tumour Biol Date: 2015-07-08
Authors: Anna P Batschauer; Nathalia G Cruz; Vanessa C Oliveira; Fernanda F Coelho; Izabela R Santos; Michelle T Alves; Ana P Fernandes; Maria G Carvalho; Karina B Gomes Journal: Mol Cell Biochem Date: 2011-05-28 Impact factor: 3.396
Authors: Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116
Authors: Mohamed A Ahmed; Edgar Selzer; Wolfgang Dörr; Gerd Jomrich; Felix Harpain; Gerd R Silberhumer; Leonhard Müllauer; Klaus Holzmann; Bettina Grasl-Kraupp; Michael Grusch; Walter Berger; Brigitte Marian Journal: Oncotarget Date: 2016-10-25